idw – Informationsdienst Wissenschaft
Nachrichten, Termine, Experten
Nachrichten, Termine, Experten
Therapy for leukemia aims at destroying all malignant cells in order to prevent the disease from recurring. However, despite all therapy efforts, some cancer cells are able to survive and can therefore result in recurrence of the disease termed minimal residual disease (MRD) by physicians. When such persistent leukemia cells are detected, treatment can often be redirected and intensified in time to cure the patient. In order to assess whether the treatment has been successful or whether the therapy must be intensified, physicians use flow cytometry and molecular biological methods to analyze blood cells. In flow cytometry, the cells flow in single file through a thin cell-sorting column which utilizes a laser beam to sort cells by size, and interior structure, as well as four additional characteristics marked by antibodies.
Dr. Richard Ratei and Dr. Leonid Karawajew from the research group of Prof. Wolf-Dieter Ludwig (Robert Rössle Clinic, Charité - University Medical Center Berlin/Helios Klinikum Berlin and Max Delbrück Center for Molecular Medicine, MDC, Berlin-Buch) have been testing multiparameter flow cytometry in patients with acute lymphoblastic leukemia (ALL). Initial results indicate that this method can be used in 90 percent of the patients with ALL. The leukemia specialists are able to detect one leukemia cell among 1,000 or 10,000 healthy cells, respectively. Now, using this technology and in cooperation with working groups in Vienna (Children's Cancer Research Institute, St. Anna Children's Hospital), Monza (Research Centre M. Tettamanti, Children's Hospital, University of Milan Bicocca) and Padua (Laboratory for Oncohematology, Department of Pediatrics, University of Padua), the prognostic significance of multiparameter flow cytometry to detect persistent leukemia cells will be investigated in an international study of children with ALL. Funding for this research project has been provided by the Wilhelm Sander Foundation (Neustadt on the Danube/Germany) which awarded the clinicians in Berlin-Buch a grant of 165,000 Euros for the next two years. Furthermore, for the first time, they will also isolate individual leukemia cells from the bone marrow or peripheral blood with the aid of flow cytometry and, using comprehensive molecular-biological analysis, identify new diagnostic markers and candidate genes for the development of innovative therapy strategies. ALL is a malignant disease occurring particularly in children. Currently, nearly 80 percent of affected children can be cured.
Press and Public Affairs
Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch
Barbara Bachtler
Robert-Rössle-Straße 10
13125 Berlin
Germany
Phone: 0049/30/94 06 - 38 96
Fax: 0049/30/94 06 - 38 33
e-mail:presse@mdc-berlin.de
http://www.mdc-berlin.de
Criteria of this press release:
Biology, Information technology, Medicine, Nutrition / healthcare / nursing
transregional, national
Research projects
English
You can combine search terms with and, or and/or not, e.g. Philo not logy.
You can use brackets to separate combinations from each other, e.g. (Philo not logy) or (Psycho and logy).
Coherent groups of words will be located as complete phrases if you put them into quotation marks, e.g. “Federal Republic of Germany”.
You can also use the advanced search without entering search terms. It will then follow the criteria you have selected (e.g. country or subject area).
If you have not selected any criteria in a given category, the entire category will be searched (e.g. all subject areas or all countries).
